4192 Stock Overview
SynCore Biotechnology Co.,Ltd, engages in development and sale of food advisory, medicine inspection, and biotechnology service in Taiwan.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
SynCore Biotechnology Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$47.80 |
| 52 Week High | NT$74.67 |
| 52 Week Low | NT$34.55 |
| Beta | 1 |
| 1 Month Change | 27.64% |
| 3 Month Change | 30.60% |
| 1 Year Change | -34.68% |
| 3 Year Change | -77.15% |
| 5 Year Change | -54.55% |
| Change since IPO | -89.08% |
Recent News & Updates
Shareholder Returns
| 4192 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | 1.1% | -1.5% | -0.6% |
| 1Y | -34.7% | 8.8% | 29.2% |
Return vs Industry: 4192 underperformed the TW Pharmaceuticals industry which returned 8.8% over the past year.
Return vs Market: 4192 underperformed the TW Market which returned 29.2% over the past year.
Price Volatility
| 4192 volatility | |
|---|---|
| 4192 Average Weekly Movement | 7.2% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in TW Market | 8.7% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 4192 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4192's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 40 | Muh-Hwan Su | www.syncorebio.com |
SynCore Biotechnology Co.,Ltd, engages in development and sale of food advisory, medicine inspection, and biotechnology service in Taiwan. The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer; and SB02, an anti-cancer NCE, which is in preclinical research for use in the treatment of stomach cancer. It also offers SB03-Veregen, an ointment for the treatment of patients with external genital and perianal warts; and SB04,an conventional drug for the treatment of age-related macular degeneration that is in Phase II clinical trials.
SynCore Biotechnology Co.,Ltd Fundamentals Summary
| 4192 fundamental statistics | |
|---|---|
| Market cap | NT$1.68b |
| Earnings (TTM) | -NT$38.17m |
| Revenue (TTM) | NT$20.20m |
83.2x
P/S Ratio-44.0x
P/E RatioIs 4192 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4192 income statement (TTM) | |
|---|---|
| Revenue | NT$20.20m |
| Cost of Revenue | NT$19.68m |
| Gross Profit | NT$521.00k |
| Other Expenses | NT$38.69m |
| Earnings | -NT$38.17m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.09 |
| Gross Margin | 2.58% |
| Net Profit Margin | -189.01% |
| Debt/Equity Ratio | 0% |
How did 4192 perform over the long term?
See historical performance and comparison